

6-25-04

grw/648

Docket No: ACY33482-00  
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Name of Applicant: Michael HAGEN  
Application No.: 10/009,473 Group Art No.: 1648  
Filed: November 8, 2001 Examiner: Le, Emily M  
For: ADJUVANT COMBINATION FORMULATIONS  
Confirmation No.: 3152  
Customer Number: 25291

Mail Stop Amendment  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicant submits herewith patents, publications, or other information of which he is aware, which he believes may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

**CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU673382593US addressed to the Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date

June 24, 2004

RoseAnn Jastrow  
RoseAnn Jastrow

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)  
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☐ Newly Cited Information  
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.

☐ Previously Cited Information  
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.


Prior application is Application Number \_\_\_\_\_, filed on \_\_\_\_\_ of \_\_\_\_\_ for \_\_\_\_\_

- ☐ Concise Explanation  
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees
- ☐ Fee for filing under 37 CFR 1.97(c) or (d)      Fee:

Instructions as to Overpayment/Underpayment:  
Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.

  
\_\_\_\_\_  
Carol E. Rozek  
Attorney for Applicants  
Reg. No. 36,993

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (845) 602-4760



Substitute for form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/009,473		
		Filing Date	November 8, 2001		
		First Named Inventor	Michael Hagen		
		Group Art Unit	1648		
Examiner Name	Emily M. Le				
Sheet	1	of	2	Attorney Docket Number	ACY33482-00

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	4,666,829			05-19-1987	
	2.	4,912,094			03-27-1990	
	3.	5,013,548			05-07-1991	
	4.	5,019,387			05-28-1991	
	5.	5,073,627			12-17-1991	
	6.	5,078,996			01-07-1992	
	7.	5,223,254			06-29-1993	
	8.	5,229,496			07-20-1993	
	9.	5,571,515			11-05-1996	
	10.	5,593,972			01-14-1997	
	11.	5,736,361			04-07-1998	
	12.	5,762,943			06-09-1998	
	13.	5,776,468			07-07-1998	
	14.	5,830,877			11-03-1998	
	15.	5,861,243			01-19-1999	
	16.	5,932,218			08-03-1999	
	17.	5,939,074			08-17-1999	
	18.	5,993,819			11-30-1999	
	19.	6,037,135			03-14-2000	

### FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	20.	EP	671,947			03-08-2000		<input type="checkbox"/>
	21.	WO	91/16819			11-14-1991		<input type="checkbox"/>
	22.	WO	95/29700			11-09-1995		<input type="checkbox"/>
	23.	WO	97/28273			08-07-1997		<input type="checkbox"/>
	24.	WO	98/17799			04-30-1998		<input type="checkbox"/>
	25.	WO	98/20734			05-22-1998		<input type="checkbox"/>
	26.	WO	98/56415			12-17-1998		<input type="checkbox"/>
	27.	WO	98/57659			12-23-1998		<input type="checkbox"/>
	28.	WO	99/02132			01-21-1999		<input type="checkbox"/>
	29.	WO	99/12565			03-18-1999		<input type="checkbox"/>
	30.	WO	99/27944			06-10-1999		<input type="checkbox"/>
	31.	WO	99/40937			08-19-1999		<input type="checkbox"/>
	32.	WO	99/51259			10-14-1999		<input type="checkbox"/>
	33.	WO	90/05147			05-17-1990		<input type="checkbox"/>

### OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	34.	Vaslin, B. et al., Vaccine 12:1132-1140 (1994).	<input type="checkbox"/>
	35.	Mosmann, T.R. et al., J Immunol 136:2348-2357 (1986).	<input type="checkbox"/>
	36.	Ahlers, J.D. et al., J Immunol 158:3947-3958 (1997).	<input type="checkbox"/>
	37.	Scharton-Kersten, T. et al., J Immunol 154:5320-5330 (1995).	<input type="checkbox"/>
	38.	Ghalib, H.W. et al., J Immunol 154:4623-4629 (1995).	<input type="checkbox"/>
	39.	Murray, H.W. and Hariprashad, J., J Exp Med 181:387-391 (1995).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/009,473
(use as many sheets as necessary)				Filing Date	November 8, 2001
				First Named Inventor	Michael Hagen
				Group Art Unit	1648
		Examiner Name	Emily M. Le		
Sheet	2	of	2	Attorney Docket Number	ACY33482-00

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T
	40.	Finkelman, F.D. and Holmes, J., Ann Rev Immunol 8:303-333 (1990).			<input type="checkbox"/>
	41.	Snapper, C.M. et al., J Exp Med 175:1367-1371 (1992).			<input type="checkbox"/>
	42.	Kobayashi, M., et al., J Exp Med 170:827-845 (1989).			<input type="checkbox"/>
	43.	Alderson, M.R. et al., J Exp Med 178:669-674 (1993).			<input type="checkbox"/>
	44.	Snapper, C.M. et al., J Immunol 154:5842-5850 (1995).			<input type="checkbox"/>
	45.	Charbit, A. et al., Vaccine 11:1221-1228 (1993).			<input type="checkbox"/>
	46.	Natuk, R.J. et al., AIDS Res Hum Retroviruses 9:395-404 (1993).			<input type="checkbox"/>
	47.	Johnson, R.P. et al., J Virol 68:3145-3153 (1994).			<input type="checkbox"/>
	48.	Fuller, D.H. et al., AIDS Res Hum Retroviruses 10:1433-1441 (1994).			<input type="checkbox"/>
	49.	Berzofsky, J.A. et al., J Clin Invest 88:876-884 (1991).			<input type="checkbox"/>
	50.	Palker, T.J. et al., J Immunol 142:3612-3619 (1989).			<input type="checkbox"/>
	51.	Hart, M.K. et al., J Immunol 145:2677-2685 (1990).			<input type="checkbox"/>
	52.	Haynes, B.F. et al., J Immunol 151:1646-1653 (1993).			<input type="checkbox"/>
	53.	Hart, M.K. et al., Proc Natl Acad Sci USA 88:9448-9452 (1991).			<input type="checkbox"/>
	54.	Bartlett, J.A. et al., AIDS 12:1291-1300 (1998).			<input type="checkbox"/>
	55.	Haynes, B.F. et al., AIDS Res Hum Retroviruses 11:211-221 (1998).			<input type="checkbox"/>
	56.	Staats, H.F. et al., J Immunol 157:462-472 (1996).			<input type="checkbox"/>
	57.	Porgador, A. et al., J Immunol 158:834-841 (1997).			<input type="checkbox"/>
	58.	Allen, T.M. et al., J Immunol 160:6062-6071 (1998).			<input type="checkbox"/>
	59.	Miller, M.D. et al., J Immunol 147:320-329 (1991).			<input type="checkbox"/>
	60.	Egan, M.A. et al., J Virol 73:5466-5472 (1999).			<input type="checkbox"/>
	61.	Kuroda, M.J. et al., J Exp Med 187:1373-1381 (1998).			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.